|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM277704502 |
| 003 |
DE-627 |
| 005 |
20250222134739.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||jpn c |
| 024 |
7 |
|
|a 10.14989/ActaUrolJap_63_10_431
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0925.xml
|
| 035 |
|
|
|a (DE-627)NLM277704502
|
| 035 |
|
|
|a (NLM)29103258
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Iwanishi, Toshichika
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Case of Castration-Resistant Prostate Cancer with Fatal Convulsive Seizure after Administration of Enzalutamide
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.01.2018
|
| 500 |
|
|
|a Date Revised 04.12.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Enzalutamide, an androgen receptor antagonist, is a standard drug for the treatment of castrationresistant prostate cancer. A 77-year-old man developed a seizure after administration of enzalutamide. The patient presented with general fatigue and high fever approximately 5 weeks after oral administration of enzalutamide. Several days later, a seizure attack occurred at home, resulting in cardiopulmonary arrest. The patient was taken to the hospital emergency room but could not be resuscitated. We described a 63-year-old man who was diagnosed with clinical T1c prostate cancer, with a Gleason score of 6 (3＋3), and a preoperative prostate-specific antigen (PSA) level of 5. 27 ng/ml. Radical prostatectomy(RP) was performed and final pathologyshowed Gleason score 3＋4, pT2c with negative surgical margin. In spite of suggested surgical radicality, PSA was 3.32, 4.78, 5.93 ng/ml, at 1, 2, and 3 months after RP, respectively. However, radiological investigation revealed no metastasis. Because of this clinical discrepancy, we checked the PSA-α1-antichemotrypsin level and found it to be ≦0.1 ng/ml. From these results, false PSA elevation caused byinterference of positive heterophilic antibodies was suggested and demonstrated byseveral immunoassays
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Prostate cancer
|
| 650 |
|
4 |
|a Seizure
|
| 650 |
|
7 |
|a Benzamides
|2 NLM
|
| 650 |
|
7 |
|a Nitriles
|2 NLM
|
| 650 |
|
7 |
|a Phenylthiohydantoin
|2 NLM
|
| 650 |
|
7 |
|a 2010-15-3
|2 NLM
|
| 650 |
|
7 |
|a enzalutamide
|2 NLM
|
| 650 |
|
7 |
|a 93T0T9GKNU
|2 NLM
|
| 700 |
1 |
|
|a Yumiba, Satoru
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koida, Youhei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kobayashi, Masao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Komori, Kazuhiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ono, Yutaka
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 63(2017), 10 vom: 05. Okt., Seite 431-433
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:63
|g year:2017
|g number:10
|g day:05
|g month:10
|g pages:431-433
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.14989/ActaUrolJap_63_10_431
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 63
|j 2017
|e 10
|b 05
|c 10
|h 431-433
|